HPR41 Are Patients With Major Depressive Disorder (MDD) Getting Access to Innovation in HTA Markets? Review of Reimbursement Decisions of Pharmacotherapies for MDD in Europe, Australia, and Canada From 2001 to 2021
Abstract
Authors
Ye Huang Lucy Sam Nilanjana Dwibedi Elio Asano Samara Ferguson